A multicenter, randomized, double-blind, placebo controlled, dose ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
About this study
This study will evaluate the safety and effectiveness of GIA632 in adults with non-segmental vitiligo that has not responded well to topical treatments, and will help identify the most suitable dose to progress into larger future trials. Eligible participants may be screened for up to four weeks before being randomly assigned to receive either GIA632 or a placebo.
Participants will attend regular clinic visits for safety checks and assessments of treatment response. Eligible participants may be invited to join an optional extension study.
- ClinicalTrials.gov Identifier: TBC
- Novartis Reference No: CGIA632B12201
- HREC Reference Number: HREC/122765/Alfred-2025
Who is eligible to participate?
- Adults ≥18 years of age with a confirmed diagnosis of non-segmental vitiligo (NSV).
- Vitiligo affecting at least 0.5% of the face and at least 3% of non-facial body areas.
- Willing and able to provide informed consent and attend required study visits.
Please note, other eligibility criteria may apply.
What is involved?
- A screening period of up to 4 weeks to check eligibility
- Attending regular study visits over the course of the study
- Completing questionnaires and assessments about your vitiligo and overall health
- Undergoing skin examinations and physical checks
- Having regular safety blood tests and routine health assessments
- Taking part in follow-up safety checks after finishing treatment
To find out more
Contact the Alfred Dermatology trials’ study coordinator: E: dermtrials@alfred.org.au | T: 03 9076 8592